絞り込み

17050

広告

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.

著者 Eggermont AMM , Kicinski M , Blank CU , Mandala M , Long GV , Atkinson V , Dalle S , Haydon A , Khattak A , Carlino MS , Sandhu S , Larkin J , Puig S , Ascierto PA , Rutkowski P , Schadendorf D , Koornstra R , Hernandez-Aya L , Di Giacomo AM , van den Eer
JAMA Oncol.2020 Jan 02 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (4view , 0users)

Full Text Sources

Medical

Whether immune-related adverse events (irAEs) indicate drug activity in patients treated with immune checkpoint inhibitors remains unknown.
PMID: 31895407 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード